Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.

Abstract:

:Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant chemotherapy before definitive radiation with its methotrexate study. Although the study was negative, RTOG has since conducted five pilot or phase II studies of neoinduction or concurrent chemotherapy with radiation therapy in patients with inoperable tumors. The last study showed that radiation concurrent with cisplatinum was tolerable with a suggestion of increased antitumor effect. In patients with potentially resectable tumors, RTOG has completed a pilot study of combination chemotherapy administered either before or after the surgery with radiotherapy. Based upon its findings, the treatment sequence, surgery-chemotherapy-radiotherapy, was chosen as the experimental arm for a new phase III study. This study was subsequently adopted by the head and neck intergroup mechanism as its study (INT 0034/RTOG 8503). RTOG has investigated the optimal timing of radiotherapy with surgery. The 7303 study established that postoperative radiotherapy achieved significantly better locoregional control but not improved absolute survival. Approximately 30% of the patients on each arm failed to complete both modalities. Even when comparison is restricted to patients who completed both modalities, postoperative radiotherapy still produced the better locoregional control. Efforts to overcome the limitations imposed by tumor hypoxia through use of carbogen (95% O2 and 5% CO2) breathing or the radiosensitizer misonidazole during radiotherapy have been unsuccessful. In a phase I study, RTOG showed that 15 to 18 sessions of sensitized radiation can be safely delivered with the new radiosensitizer SR 2508 in contrast to only six such sessions with misonidazole. This promising radiosensitizer is now being tested in a phase III trial. RTOG has also investigated variations in fraction size, fraction number, and total radiation dose. In the 7102 study, split-course irradiation achieved equivalent antitumor results as compared to continuous daily irradiation but with less social alteration and cost to the patient. In the hyperfraction pilot study 7703, twice a day irradiation with 120 cGys up to 6,000 cGys proved to be tolerable.(ABSTRACT TRUNCATED AT 400 WORDS)

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

subject

Has Abstract

pub_date

1988-02-01 00:00:00

pages

39-60

issue

1

eissn

0093-7754

issn

1532-8708

journal_volume

15

pub_type

临床试验,杂志文章
  • Metastatic and histologic presentations in unknown primary cancer.

    abstract::The patient with metastatic adeno- or undifferentiated carcinoma who presents with a cryptic primary is subjected to an extensive diagnostic search. These efforts apparently stem from the following assumptions: 1). The ultimately proven primary sites in such patients will occur with the same frequency as the most comm...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Nystrom JS,Weiner JM,Heffelfinger-Juttner J,Irwin LE,Bateman JR,Wolf RM

    更新日期:1977-03-01 00:00:00

  • Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.

    abstract::The ability of dexrazoxane (DEX) to protect against doxorubicin (DOX)-induced cardiomyopathy has been demonstrated in mice, normotensive and hypertensive rats, rabbits, dogs, swine, and humans. These animal models of DOX-induced cardiomyopathy were found to be highly predictive of DEX activity clinically. In mice admi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Imondi AR

    更新日期:1998-08-01 00:00:00

  • Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.

    abstract::In spite of the chemosensitivity seen with the initial treatment of malignant lymphoid disorders, relapse is common and death most often occurs as a result of disease progression. This is related to a multitude of resistance mechanisms associated with the various lymphoproliferative disorders. As a result, therapies t...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Byrd JC,Grever MR,Waselenko JK,Willis CR,Park K,Goodrich A,Lucas MA,Shinn C,Flinn IW

    更新日期:2000-04-01 00:00:00

  • Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.

    abstract::Based on promising results with 5-FU/FA or 5-FU/IFN-alpha in colorectal cancer, a pilot study was initiated to evaluate the effects of the combination 5-FU/FA/interferon alfa (IFN-alpha) in patients with advanced pancreatic cancer. Patients received 9 million units (MU) IFN-alpha subcutaneously three times a week or 6...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Knuth A,Bernhard H,Klein O,Meyer zum Büschenfelde KH

    更新日期:1992-04-01 00:00:00

  • Factors influencing quality of life in cancer patients: anemia and fatigue.

    abstract::Anemia is a multi-symptom syndrome involving both physical and emotional problems that can be evaluated for their impact on quality of life. Fatigue is the cardinal symptom of anemia, reported by three of four cancer patients using the general version of the Functional Assessment of Cancer Therapy (FACT-G) questionnai...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Cella D

    更新日期:1998-06-01 00:00:00

  • Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea.

    abstract::Preclinical studies have indicated that hydroxyurea leads to enhancement of 5-fluorouracil (5-FU) activity when given after 5-FU. This is presumably due to hydroxyurea's actions resulting in maintaining low levels of deoxyuridine monophosphate pools. The combination of hydroxyurea and 5-FU has been tested in several i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Muggia FM,Moran RG

    更新日期:1992-06-01 00:00:00

  • Secondary chemoprevention of upper aerodigestive tract tumors.

    abstract::Patients with successfully treated upper aerodigestive tract (UADT) tumors commonly develop second primary tumors (SPTs). These tumors occur more often than chance would predict, arise in both the upper or lower aerodigestive tracts, are frequently preceded by leukoplakia, and are a major cause of treatment-related fa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90048-x

    authors: Anderson WF,Hawk E,Berg CD

    更新日期:2001-02-01 00:00:00

  • Bladder cancer in Africa: update.

    abstract::Carcinoma of the bladder is the most prevalent cancer in Egypt and in most African countries. At the National Cancer Institute (NCI), Cairo, it constitutes 30.3% of all cancers. The median age at diagnosis is 46 years, with a male preponderance of 5:1. Whether in Egypt or other African countries such as Sudan, Kenya, ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2001.21961

    authors: el-Mawla NG,el-Bolkainy MN,Khaled HM

    更新日期:2001-04-01 00:00:00

  • Reirradiation of recurrent head and neck cancers with curative intent.

    abstract::In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.003

    authors: Chmura SJ,Milano MT,Haraf DJ

    更新日期:2004-12-01 00:00:00

  • Inflammatory breast cancer: patient advocate view.

    abstract::Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, often presenting with distant metastasis. While controversy exists regarding the actual incidence of the disease, there is agreement that IBC causes a disproportionate number of breast cancer deaths. Those with typical IBC symptoms face a h...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.11.011

    authors: Mason G,Johnson O

    更新日期:2008-02-01 00:00:00

  • Are sex discordant outcomes in COVID-19 related to sex hormones?

    abstract::COVID-19 has a clear sex disparity in clinical outcome. Globally, infection rates between men and women are similar; however, men are more likely to have more severe disease and are more likely to die. The causes for this disparity are currently under investigation and are most likely multifactorial. Sex hormones play...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.06.002

    authors: Strope JD,Chau CH,Figg WD

    更新日期:2020-10-01 00:00:00

  • Diagnosis and treatment of metastatic disease to the liver.

    abstract::A number of cancers present with synchronous or metachronous hepatic metastases. Historically, many of these patients were considered unresectable and were treated with either systemic chemotherapy or supportive care. Today, a variety of options exist for the management of hepatic metastases. Newer agents for systemic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.12.004

    authors: Arciero CA,Sigurdson ER

    更新日期:2008-04-01 00:00:00

  • The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.

    abstract::Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1016/s0093-7754(01)90260-x

    authors: Coleman RE,Seaman JJ

    更新日期:2001-04-01 00:00:00

  • Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

    abstract::Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor family, which produces factors that are considered to be important mediators of cell growth. Overexpression of HER2, which occurs in approximately 25% to 30% of human breast cancers, has fostered considerable interest i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ewer MS,Gibbs HR,Swafford J,Benjamin RS

    更新日期:1999-08-01 00:00:00

  • Defining the clinical diagnosis of inflammatory breast cancer.

    abstract::Inflammatory breast cancer (IBC) is an extremely aggressive disease that progresses rapidly and carries a very grim prognosis. It is characterized by erythema, rapid enlargement of the breast, skin ridging, and a characteristic peau d'orange appearance of the skin secondary to dermal lymphatic tumor involvement. Altho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.11.010

    authors: Singletary SE,Cristofanilli M

    更新日期:2008-02-01 00:00:00

  • Paclitaxel in the treatment of esophageal cancer.

    abstract::Since its introduction, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antitumor activity in epidermoid carcinomas and adenocarcinomas originating in the esophagus. Paclitaxel is the most active single agent available to treat metastatic esophageal cancer. Combinations of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Weiner LM

    更新日期:1999-02-01 00:00:00

  • The role of interferon in the therapy of epidemic Kaposi's sarcoma.

    abstract::Kaposi's sarcoma (KS) is the major neoplastic complication of the acquired immune deficiency syndrome (AIDS). Although most patients succumb to infectious complications of AIDS rather than as a direct consequence of the tumor, KS may, in some cases, pursue an aggressive clinical course resulting in considerable morbid...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Krown SE

    更新日期:1987-06-01 00:00:00

  • Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.

    abstract::The side effects of cisplatin (75 mg/m2) in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (175 mg/m2 over 3 hours) are expected to be more severe and frequent than those of carboplatin (area under the concentration-time curve of 5) in combination with the same dose of paclitaxel, but...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Neijt JP,Engelholm SA,Witteveen PO,Tuxen MK,Sørensen PG,Hansen M,Hirsch F,Sessa C,de Swart C,van Houwelingen HC,Lund B,Hansen SW

    更新日期:1997-10-01 00:00:00

  • Biochemical effects of Navelbine on tubulin and associated proteins.

    abstract::Navelbine (NVB) or 5' nor-anhydro-vinblastine was shown to present a broader antitumor activity and to induce fewer side effects than vinblastine (VBL) or vincristine (VCR). The possible mechanisms of these differences were analyzed with in vitro methods. At substoichiometric concentrations, the three drugs inhibit mi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Fellous A,Ohayon R,Vacassin T,Binet S,Lataste H,Krikorian A,Couzinier JP,Meininger V

    更新日期:1989-04-01 00:00:00

  • Common complications of advanced cancer.

    abstract::Complications due to cancer and its treatment are common and increase in incidence and severity as the disease progresses. Central nervous system complications affect 15% to 20% of patients, and up to 75% have bone metastases at some point during the disease process. Endocrine abnormalities include hypercalcemia, adre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Nelson KA,Walsh D,Abdullah O,McDonnell F,Homsi J,Komurcu S,LeGrand SB,Zhukovsky DS

    更新日期:2000-02-01 00:00:00

  • Lymphoma: diagnosis, staging, natural history, and treatment strategies.

    abstract::Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.01.008

    authors: Zinzani PL

    更新日期:2005-02-01 00:00:00

  • The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

    abstract::Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Laport GF,Williams SF

    更新日期:1998-08-01 00:00:00

  • Autoimmune complications of chronic lymphocytic leukemia.

    abstract::Autoimmune complications are common in chronic lymphocytic leukemia (CLL), occurring in up to a quarter of all patients during the course of the illness. By far the most common manifestation is autoimmune hemolytic anemia (AIHA), followed by immune thrombocytopenia (ITP). It is not true to say that autoimmunity is con...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.01.011

    authors: Hamblin TJ

    更新日期:2006-04-01 00:00:00

  • Opportunities and challenges in the development of targeted therapies.

    abstract::Expanding knowledge about basic biology and a detailed understanding of the signaling pathways that participate in the growth and metastasis of breast cancer have identified opportunities for diagnostic and therapeutic intervention. Endocrine therapy represents the first and most successful example of targeted therapy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.01.003

    authors: Hortobagyi GN

    更新日期:2004-02-01 00:00:00

  • Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review.

    abstract::Follicular lymphoma is a low-grade, indolent non-Hodgkin's lymphoma characterized by the presence of the t(14;18) translocation. The detection of this translocation using polymerase chain reaction techniques has been increasingly studied. However, the diagnostic and prognostic value of detecting t(14;18) rearrangement...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bordeleau L,Berinstein NL

    更新日期:2000-12-01 00:00:00

  • Surgical therapy of lung metastases.

    abstract::Almost 125 years after the first documented case, pulmonary metastasectomy is still poorly understood. No other organ is subject to the wide histologic variety of metastatic insults, and this fact has complicated a complete exposition of when pulmonary metastasectomy may be beneficial. Many physicians still consider p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.03.004

    authors: Sternberg DI,Sonett JR

    更新日期:2007-06-01 00:00:00

  • Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.

    abstract::This phase I dose-escalation study was undertaken to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and ifosfamide that could be administered without growth factors to previously untreated patients with non-small cell lung cancer. Forty patients with advanced n...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Shepherd FA,Latreille J,Paul K,Eisenhauer E

    更新日期:1996-12-01 00:00:00

  • Symptom control in advanced cancer.

    abstract::Most important is the physician's attitude, energy, and skill focused toward helping the patient through the difficulties in the last weeks of life. Many causes of nausea, dyspnea, and other troublesome symptoms can be effectively treated, and pharmacologic palliation is nearly always possible. A multidisciplinary tea...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Storey P

    更新日期:1994-12-01 00:00:00

  • The development of busulfan/cyclophosphamide preparative regimens.

    abstract::Bone marrow transplantation (BMT) preparative regimens consisting of busulfan (Bu) and cyclophosphamide (Cy) were developed as an alternative to preparative regimens based on total body irradiation (TBI). Animal studies demonstrated that Bu had a high level of myeloablative and antileukemic activity, but little immuno...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Santos GW

    更新日期:1993-08-01 00:00:00

  • Improving patient care through molecular diagnostics.

    abstract::Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.017

    authors: Perez EA,Pusztai L,Van de Vijver M

    更新日期:2004-10-01 00:00:00